By leveraging the sensing technologies and valuable insights developed in medical fields up to now, the Company will be focusing on the development of solutions for: cardiovascular diseases which have been leading causes of death worldwide; respiratory diseases, since the number of people suffering from them is growing particularly in emerging economies; and pain management that causes significant impact on people’s daily lives. Focus and commitment to these efforts will allow OMRON Group to realize the long-term vision.

1. Cardiovascular business:
Zero cerebrovascular and cardiovascular events

An estimated one billion people worldwide have hypertension. Hypertension may cause cerebro-cardiovascular diseases (events) such as strokes and heart failure while symptoms go unnoticed. Since the release of the first blood pressure monitor in 1973, the Company has always been focusing on developing easy-to-use and accurate blood pressure monitors as well as conducting educational activities for promoting blood pressure monitoring at home. The cumulative global sales of OMRON blood pressure monitors exceeded 300 million units in 2021. While home blood pressure monitoring continues to become more popular worldwide, deaths resulting from cerebrovascular and cardiovascular events and individuals requiring long-term nursing care remain on the rise.

To accomplish the business vision of the cardiovascular domain, the Company will expand the target fields from monitoring cardiac dysfunction for the early detection, to the development of an upper-arm blood pressure monitor with built-in ECG technology, and the global launch of ECG analysis service. The Company also will expand business fields to include “the early detection and recurrence prevention of atrial fibrillation.” As the life-style diseases are known to be risk factors of hypertension and atrial fibrillation, the Company will contribute to the development of new devices and services for early detection and improvements of these types of diseases. In addition, AI-based algorithm developments for establishing the framework of preventive care are being launched.

On the global businesses, the Company will focus on the reinforcement of partnerships with doctors and medical institutions in mainland China, where the population with hypertension and respiratory disease is trending up, and improve the services fostering the relationship between patients and physicians via MMC Health Convenience Stores¹. In India, the Company set up experience centers throughout the nation to provide Indian consumers a hands-on experience with OMRON products. It will further spread the benefits of home blood pressure monitoring in the country.

2. Respiratory business:
Zero aggravation of respiratory diseases

Respiratory business will expand target diseases by adding COPD² to the former asthma target. The number of patients suffering from respiratory disease is growing, mainly in emerging economies. As diagnostic criteria are not clearly quantified, clearly diagnostic decisions are difficult for physicians to make. The Company will be distributing devices to support treatments and diagnosis in emerging nations lacking fully established medical systems. And for general households, especially in developed countries, the Company will be promoting symptom control and care services to alleviate soaring medical expenditures to relieve the burden of patients and their families.

3. Pain management:
Zero restrictions on daily activities due to chronic pain

Within the pain management domain, the Company will focus on the development of devices incorporating new transcutaneous electrical nerve stimulation (TENS) technology, as well as providing an exercise therapy support service. The Company’s aim here is to help more people lead their daily lives without worrying about pain.

On April 1, 2022, a special web page of SF2030 was added to OMRON Healthcare’s corporate website.
Among others it contains OMRON Healthcare's Long-term Vision SF2030 Video which portrays the lives of people in society where "Going for ZERO" has been realized.

The SF2030 special webpage available at the below URL: 
https://healthcare.omron.com/news-media/events/sf2030

The Long-term Vision SF2030 video can be seen here:
https://www.youtube.com/watch?v=6cv9Le-6c0I

Contact

Matthieu Valk, Yoichi Tomita

Global Communication Administration
Public Relations Department
OMRON Healthcare Co., Ltd.

Tel: +81-75-925-2004

Email: pr-ohq@omron.com

Fax: +81-75-925-2005

Address: 53 Kunotsubo, Terado-cho, Muko City, Kyoto 617-0002, Japan